INOVIO PHARMACEUTICALS, INC. for INOVIO PHARMACEUTICALS, INC.
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Issues related to Oncology Next Generation COVID-19 vaccines; Medicare Part B and HPV; Orphan Drug Act of 1983 Orphan Drug Tax Credit - The Build Back Better Act, H.R. 5673; Accelerated Approval Integrity Act of 2022, H.R. 6963; Prescription Drug User Fee Act (PDUFA); Medical Device User Fees Amendments (MDUFA IV); Prevent Pandemics Act, S. 3799; Cures 2.0, H.R. 6000; Issues related to BARDA/ASPR and manufacturing of COVID-19 vaccines and therapies TRIPS Waiver for COVID-19 vaccines and therapies; Outreach to Colombian Congressional Caucus on COVID-19
| Lobbyist | Covered position, as disclosed |
|---|---|
| COOKAB HASHEMI | — |
Budget/Appropriations BUD
COVID-19 Supplemental Appropriations Act of 2022, H.R. 7007, AG/FDA FY2023 appropriations, State, Foreign Ops FY2023 appropriations; LHHS FY2023 appropriations
| Lobbyist | Covered position, as disclosed |
|---|---|
| COOKAB HASHEMI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.